Capital Market Strategies’s AstraZeneca AZN Stock Holding History

Capital Market Strategies’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,546	Closed	-$227K	–	141
2025 Q1	$227K	Hold	1,546	–	–	0.15%	127
2024 Q4	$203K	Hold	1,546	–	–	0.12%	144
2024 Q3	$241K	Sell	1,546 -134	-8%	-$21.6K	0.15%	132
2024 Q2	$262K	Hold	1,680	–	–	0.17%	123
2024 Q1	$228K	Sell	1,680 -36	-2%	-$4.77K	0.17%	127
2023 Q4	$231K	Hold	1,716	–	–	0.2%	126
2023 Q3	$227K	Hold	1,716	–	–	0.23%	115
2023 Q2	$246K	Buy	+1,716	New	+$252K	0.23%	115
2023 Q1	–	Sell	-1,716	Closed	-$233K	–	48
2022 Q4	$233K	Buy	+1,716	New	+$215K	0.25%	111
2022 Q3	–	Sell	-1,966	Closed	-$260K	–	136
2022 Q2	$260K	Hold	1,966	–	–	0.27%	100
2022 Q1	$261K	Sell	1,966 -717	-27%	-$86K	0.23%	120
2021 Q4	$313K	Buy	+2,683	New	+$316K	0.26%	102

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Market Strategies's AZN Position: Q2 2025 in Review

Capital Market Strategies sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 1,546 shares — an estimated $227K sold.

Capital Market Strategies first reported a position in AZN in Q4 2021 and held it in 12 quarters. The position peaked at $313K in Q4 2021. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Capital Market Strategies reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Capital Market Strategies sold 1,546 AstraZeneca shares in Q2 2025, an estimated $227K.
Capital Market Strategies first reported a position in AstraZeneca in Q4 2021 and held it in 12 quarters.
Capital Market Strategies's AstraZeneca position peaked at $313K in Q4 2021.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Capital Market Strategies's 13F filing for Q2 2025, filed 2 Jul 2025.